SR9009 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-15. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Austin was contacted by Paul Heyman of Extreme Championship Wrestling (ECW), who had previously managed him in WCW. Heyman hired him to do promos and in-ring interviews as he had not adequately recovered from his injury, paying Austin $500 (equivalent to $1,056 in 2025) a night. Changing his nickname to "Superstar", Austin debuted in ECW at Gangstas Paradise on September 18, 1995. While in ECW, Austin used the platform to develop his future "Stone Cold" persona as well as a series of vignettes running down WCW in general and Bischoff in particular, most memorably in several promos that mocked his then-status as Nitro host by introducing Monday NyQuil, where he was joined by "Bongo" (a set of drums, meant to represent Steve "Mongo" McMichael) in promoting the show "where the big boys play with each other." Several wrestlers have credited ECW as the place where Austin developed his microphone skills. Austin has credited Heyman as the man who taught him how to cut a promo. Whipwreck, who was the ECW World Heavyweight Champion at the time, defeated Austin in an upset to retain the championship at November to Remember on November 18. At December to Dismember on December 9, Whipwreck defended the title against Austin and The Sandman in a three way dance. Austin eliminated Whipwreck from the match by pinning him following a Stun Gun, but was pinned himself after The Sandman punched him using brass knuckles.
==== Contemporary slavery and forced labor ==== The number of slaves today remains as high as 12 million to 27 million. This is probably the smallest proportion of slaves to the rest of the world's population in history. Most are debt slaves, largely in South Asia, who are under debt bondage incurred by lenders, sometimes even for generations. It is the fastest growing criminal industry and is predicted to eventually outgrow drug trafficking.
Sick animals often seek out and eat plants containing compounds like tannins and alkaloids to help purge parasites—a behavior observed by scientists and sometimes cited by indigenous healers as the source of their knowledge.
=== Princess Elizabeth and Philip Mountbatten's wedding cake === Princess Elizabeth and Philip Mountbatten were offered many cakes from well-wishers around the world for their wedding on 20 November 1947. Of these they accepted only 12, including one from J. Lyons and Co. They created a three-tiered cake, mounted on a silver stand, made by F E Jacobs, chief decorator of J Lyons' Ornamental Department. It stood 1.8 metres high and weighed 63 kg. The first and second tiers featured specially commissioned 10 cm blue and white Wedgwood Jasper vases set in alcoves behind silver pillars, with smaller vases on the third tier. The cake's panels depicted Princess Elizabeth's coat of arms, the couple's initials and a Naval crown. Atop the third tier sat a larger Jasper vase, filled with fresh flowers and trailing orange blossom.
organized criminal: structured group, three or more people, one or more serious crimes, in order to obtain financial or other material benefit; serious crime: offense punishable by at least four years in prison; and, structured group: Not randomly formed but does not need formal structure, Others stress the importance of power, profit and perpetuity, defining organized criminal behavior as:
Sources: en.wikipedia.org
== Philanthropy == Kimmel was an important benefactor of New York University donating $10 million in 2005 and $15 million in 2006 to fund the Helen and Martin Kimmel Center for Stem Cell Biology, creating a professorship of molecular immunology, and contributing to the construction of the Helen and Martin Kimmel Center for University Life which houses the Skirball Center for the Performing Arts. Kimmel is also a significant contributor to the Weizmann Institute of Science in Rehovot, Israel funding the Helen and Martin Kimmel Institute for Magnetic Resonance, the Helen and Martin Kimmel Center for Molecular Design, the Helen and Martin Kimmel Hyperbaric & Advanced Wound Healing Center, and the Kimmel Center for Archaeological Science. Kimmel was a long time supporter of the Jewish Museum in New York City. Kimmel served as a trustee of New York University Langone Medical Center.
electron transport in the mitochondrial ETC, by shuttling electrons from mitochondrial complexes like nicotinamide adenine dinucleotide (NADH), ubiquinone reductase (complex I), and succinate ubiquinone reductase (complex II), the fatty acids and branched-chain amino acids oxidation (through flavin-linked dehydrogenases) to ubiquinol–cytochrome-c reductase (complex III) of the ETC: CoQ10 participates in fatty acid and glucose metabolism by transferring electrons generated from the reduction of fatty acids and glucose to electron acceptors; antioxidant activity as a lipid-soluble antioxidant together with vitamin E, scavenging reactive oxygen species and protecting cells against oxidative stress, inhibiting the oxidation of proteins, DNA, and use of vitamin E.
The colloidal gold protein assay is a highly sensitive biochemical assay for determining the total concentration of protein in a solution (~0.1 ng/μL to 200 ng/μL). It was first described in 1987 by two groups who used commercially available "Aurodye" colloidal gold solutions. Notably, the formulation of Aurodye changed between 1987 and 1990 such that it became incompatible with protein assays, however vendors such as Bio-Rad & Diversified Biotech starting offering colloidal gold formulations that were suitable for protein assays. These products have since been discontinued and there are no vendors that currently explicitly sell colloidal gold for the assay, however detailed synthetic procedures were published to produce the ~17-40 nm gold nanoparticles that are suitable for the assay, along with modifications to increase the shelf stability of the colloidal gold & adapt the assay to microplate format & increase its sensitivity. Gold nanoparticles in the ~17-40 nm size range that are presumably compatible with the assay are currently commercially available.
=== Subsequent history === The discovery of TOR and mTOR stemmed from independent studies of the natural product rapamycin by Joseph Heitman, Rao Movva, and Michael N. Hall in 1991; by David M. Sabatini, Hediye Erdjument-Bromage, Mary Lui, Paul Tempst, and Solomon H. Snyder in 1994; and by Candace J. Sabers, Mary M. Martin, Gregory J. Brunn, Josie M. Williams, Francis J. Dumont, Gregory Wiederrecht, and Robert T. Abraham in 1995. In 1991, working in yeast, Hall and colleagues identified the TOR1 and TOR2 genes. In 1993, Robert Cafferkey, George Livi, and colleagues, and Jeannette Kunz, Michael N. Hall, and colleagues independently cloned genes that mediate the toxicity of rapamycin in fungi, known as the TOR/DRR genes. Rapamycin arrests fungal activity at the G1 phase of the cell cycle. In mammals, it suppresses the immune system by blocking the G1 to S phase transition in T-lymphocytes. Thus, it is used as an immunosuppressant following organ transplantation. Interest in rapamycin was renewed following the discovery of the structurally related immunosuppressive natural product FK506 (later called Tacrolimus) in 1987. In 1989–90, FK506 and rapamycin were determined to inhibit T-cell receptor (TCR) and IL-2 receptor signaling pathways, respectively. The two natural products were used to discover the FK506- and rapamycin-binding proteins, including FKBP12, and to provide evidence that FKBP12–FK506 and FKBP12–rapamycin might act through gain-of-function mechanisms that target distinct cellular functions.
The Organisation for Economic Co-operation and Development (OECD; French: Organisation de coopération et de développement économiques, OCDE) is an intergovernmental organisation with 38 member countries. It was founded in 1961 to stimulate economic progress and world trade. The OECD is a forum whose member countries describe themselves as committed to democracy and the market economy, providing a platform for collective problem-solving, analysis, and coordination. In 2026, their collective population was 1.38 billion people with high levels of human development. As of 2026, OECD member countries collectively comprised 58.4% of global nominal GDP and 38.9% of global GDP at purchasing power parity. The OECD is an official United Nations observer. Member states have strong social security systems. The OECD is headquartered at the Château de la Muette in Paris, France. The OECD is funded by contributions from member countries and publishes annual reports on economic data as well as a variety of evaluations and rankings.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.